Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling

HIGHLIGHTS

  • who: Teja Devarakonda from the DivisionCommonwealth University have published the research: Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling, in the Journal: Scientific Reports Scientific Reports
  • what: The authors report a novel finding involving the association of relaxin treatment and reduced induction of autophagy in the failing myocardium 28 days post MI. All experiments in this study were performed in strict adherence to guidelines for the case and use of laboratory animals, as updated by the NIH (8th edition, 2011), and this study . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?